Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients With Chronic Obstructive Pulmonary Disease Receiving Pravastatin

Tsung-Ming Lee, Mei S. Lin, Nen Chung Chang

Research output: Contribution to journalArticle

115 Citations (Scopus)

Abstract

Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high-sensitivity C-reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double-blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months. Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54% from 599 ± 323 seconds at baseline to 922 ± 328 seconds at the end (p

Original languageEnglish
Pages (from-to)530-535
Number of pages6
JournalAmerican Journal of Cardiology
Volume101
Issue number4
DOIs
Publication statusPublished - Feb 15 2008

Fingerprint

Pravastatin
C-Reactive Protein
Chronic Obstructive Pulmonary Disease
Interleukin-6
Exercise
Placebos
Random Allocation
Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{850877152ce64632b1adcc5c95ddb99c,
title = "Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients With Chronic Obstructive Pulmonary Disease Receiving Pravastatin",
abstract = "Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high-sensitivity C-reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double-blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months. Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54{\%} from 599 ± 323 seconds at baseline to 922 ± 328 seconds at the end (p",
author = "Tsung-Ming Lee and Lin, {Mei S.} and Chang, {Nen Chung}",
year = "2008",
month = "2",
day = "15",
doi = "10.1016/j.amjcard.2007.09.102",
language = "English",
volume = "101",
pages = "530--535",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Usefulness of C-Reactive Protein and Interleukin-6 as Predictors of Outcomes in Patients With Chronic Obstructive Pulmonary Disease Receiving Pravastatin

AU - Lee, Tsung-Ming

AU - Lin, Mei S.

AU - Chang, Nen Chung

PY - 2008/2/15

Y1 - 2008/2/15

N2 - Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high-sensitivity C-reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double-blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months. Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54% from 599 ± 323 seconds at baseline to 922 ± 328 seconds at the end (p

AB - Inflammation is increased in chronic obstructive pulmonary disease (COPD) and plays a role in exercise intolerance. We investigated whether pravastatin administration is effective in improving exercise capacity in patients with COPD, and whether baseline or serial changes in high-sensitivity C-reactive protein (hs-CRP) over time are associated with corresponding changes in exercise capacity. In a randomized, double-blinded, and parallel design, 125 patients with clinically stable COPD were randomly assigned to receive placebo or pravastatin (40 mg/day) over a period of 6 months. Plasma hs-CRP levels were measured before randomization and during follow-up. Baseline characteristics were similar in the 2 groups. Exercise time remained stable throughout the study in the placebo group. Exercise time increased by 54% from 599 ± 323 seconds at baseline to 922 ± 328 seconds at the end (p

UR - http://www.scopus.com/inward/record.url?scp=38849125493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849125493&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.09.102

DO - 10.1016/j.amjcard.2007.09.102

M3 - Article

C2 - 18312772

AN - SCOPUS:38849125493

VL - 101

SP - 530

EP - 535

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 4

ER -